ClinicalTrials.gg
Not yet recruitingNCT07132008Updated Aug 20, 2025

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

A Phase 3 interventional study of Tislelizumab and Oxaliplatin in Colonic Neoplasms, Neoadjuvant Therapy and Immune Checkpoint Inhibitors, sponsored by First Affiliated Hospital of Guangxi Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-20.

Sponsored by First Affiliated Hospital of Guangxi Medical University · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 211 studies in Colonic Neoplasms with a site in China — 101 open to participants now, 117 under way, 22 of them phase 3. Colonic Neoplasms · China.

Planned enrollment
91st of 163
94 · median 110
Started
2025
with 17 others
Phase 3
28 of 211
15 open now
Primary completion
2027-09
later than 76 of 116 live
Registered
180th of 211
by date

Among the 211 studies in Colonic Neoplasms with a site in China, this one is the 91st largest by planned enrollment of the 163 interventional ones that give a count, is one of 18 that started in 2025, is one of 28 in phase 3, reaches primary completion later than 76 of the 116 other live ones, and was the 180th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

101 of the 211 studies in Colonic Neoplasms with a site in China are open now. Recruiting first, the newest first:

96 more — sign in →

All 101 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 211 studies in Colonic Neoplasms with a site in China, or all of them as a file.
02

Study summary

Building on earlier exploratory work, this study further designs a multi-institutional, prospective, randomized clinical trial to evaluate the efficacy and safety of the combination therapy of the immune checkpoint inhibitor Tislelizumab with CAPOX for neoadjuvant treatment in high-risk locally advanced MSS-type colorectal cancer, as well as its impact on patient outcomes. This study aims to provide new evidence for the clinical practice of treating MSS-type colorectal cancer.

Read the detailed description

Patients were randomly assigned to either the experimental group, receiving neoadjuvant therapy with Tislelizumab combined with CAPOX, or the control group, receiving neoadjuvant CAPOX chemotherapy alone. Patients in the experimental group underwent four cycles of neoadjuvant CAPOX chemotherapy plus Tislelizumab prior to surgery. Patients in the control group received four cycles of neoadjuvant CAPOX chemotherapy alone. Patients deemed eligible for R0 resection based on radiographic assessment proceeded to radical colorectal cancer surgery. Following surgery, patients in both groups were to complete an additional four cycles of CAPOX chemotherapy. We compared and analyzed the short- and long-term clinical outcomes between the Tislelizumab plus CAPOX regimen and CAPOX alone for the treatment of microsatellite stable (MSS)-type high-risk locally advanced colon cancer (stages T4NanyM0 or TanyN+M0).

03

Conditions studied

  • Colonic Neoplasms
  • Neoadjuvant Therapy
  • Immune Checkpoint Inhibitors

Browse trials for

Keywords

  • Colon cancer
  • Neoadjuvant chemotherapy
  • PD-1 inhibitor
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years old and ≤75 years old.
  • diagnosed MSS ((confirmed by microsatellite stable detection or next-generation target sequencing) or (confirmed by immunohistochemistry)) colon adenocarcinoma.
  • The lower edge of the tumor is more than 12cm from the anus as measured by colonoscopy and the lower edge of the tumor cannot be directly palpated during rectal examination.
  • Enhanced CT stage T4 or T1-4 N+ without multiple primary tumors or distant .
  • The physical status score is 0-1.
  • is expected to be more than 1 year.
  • First diagnosis, no previous anti-tumor treatment received, and no chemotherapy .
  • Appropriate organ function is defined as follows: level ≥ 60g/L, ≥ 1.5×10\^9/L, count ≥ 75×10\^9/L, Serum total ≤ 1.5× the (UNL), (AST) ≤ 2× UNL, Alanine aminotransferase (ALT) ≤ 3× UNL, Serum creatinine ≤ 1.5× UNL.
  • , able to understand the study protocol and willing to participate in the study, and will provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Enhanced CT stage (T1-3N0M0)
  • Multifocal colorectal cancer.
  • CT or MRI in the mid-sagittal plane shows that the lower border of the tumor is below the line connecting the sacrococcygeal promontory and the upper border of the pubic symphysis.
  • Tumor obstruction or high risk of obstruction, bleeding, and/or perforation requiring emergency surgery or stent placement.
  • Cannot tolerate chemotherapy or immunotherapy, such as but not limited to bone marrow suppression.
  • History of malignant tumors, except for basal cell carcinoma, papillary thyroid carcinoma, and various in situ cancers.
  • Acute exacerbation of important organ diseases (such as but not limited to , coronary heart disease, and renal insufficiency) and/or severe acute infectious diseases (such as but not limited to hepatitis, pneumonia, and myocarditis), score > 3 points.
  • Mental disorders, illiteracy, or language communication barriers that prevent the understanding of the study protocol.
  • Peripheral sensory neuropathy, unable to receive oxaliplatin-based chemotherapy.
  • Continuous use of for more than 3 days within 1 month prior to signing the form, or having comorbidities requiring the use of glucocorticoid therapy.
  • Unable to undergo enhanced CT examination
  • Pregnancy or lactation.
  • Refused to participate in this study.
  • Other situations in which the researcher deems unsuitable for this study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
94 participants (estimated)

Study arms

  • Experimental
    CAPOX combined with Tislelizumab

    Patients in the experimental group underwent two or four cycles of preoperative CAPOX combined with Tislelizumab. Patients assessed as suitable for R0 resection by imaging underwent radical colectomy. Following surgery, all patients in both groups completed an additional four or six cycles of adjuvant CAPOX chemotherapy.

    Drug: Tislelizumab · Drug: Oxaliplatin · Drug: Capecitabine

  • Placebo comparator
    CAPOX chemotherapy

    Patients in the experimental group underwent two or four cycles of preoperative CAPOX combined with placebo. Patients assessed as suitable for R0 resection by imaging underwent radical colectomy. Following surgery, all patients in both groups completed an additional four or six cycles of adjuvant CAPOX chemotherapy.

    Drug: Oxaliplatin · Drug: Capecitabine

Interventions

  • 200 mg on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The incidence of adverse events with Tislelizumab is relatively low. The Tislelizumab dose adjustment was implemented according to the prescribing information.

    Also known as: Baizean

  • Oxaliplatin 130mg/m2 on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.

    Also known as: Eloxatin

  • Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.

    Also known as: Xeloda

06

What researchers measure

Primary outcomes

  1. Pathological complete response (pCR)

    the proportion of tumor regression grades 0 (TRG0, disappearance of tumor cells) in the pathological specimens of surgically resected tumors.

    Time frame: 3-5 days of postoperative pathological examination

Secondary outcomes

  1. R0 resection

    the rate of a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed.

    Time frame: 3-5 days of postoperative pathological examination

  2. Disease-free survival (DFS)

    3-year disease-free survival

    Time frame: From date of the patient signs the informed consent form until the date of earliest occurrence of the patient's tumor recurrence or death, whichever came first, assessed up to 36 months.

  3. Overall survival (OS)

    3-year overall survival

    Time frame: From the date of the patient signs the informed consent form until the date of the patient's death, assessed up to 36 months.

  4. Adverse events (AEs)

    the rate of adverse events

    Time frame: up to half a year

  5. Immune-related adverse events (irAEs)

    the rate of immune-related adverse events

    Time frame: up to half a year

  6. Surgical complication

    the rate of surgical complication during or after operation.

    Time frame: From the day of surgery to 30 days after the operation, including intraoperative and postoperative complications.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Sep 2027, 23 months later.

Of 55 non-industry phase 3 interventional studies under Colonic Neoplasms, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 123. This study's planned 23 months is below that.

Counting every sponsor, half of 72 studies reached it within 55 months; a quarter within 37 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2025
First posted
Aug 20, 2025
StartEst.
Oct 1, 2025
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2030
Last update
Aug 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07132008
Lead sponsor
First Affiliated Hospital of Guangxi Medical University
Collaborators
The First Affiliated Hospital of Xiamen University, The First Affiliated Hospital of University of South China
Responsible party
Sponsor
First posted
Aug 20, 2025
Start date
Oct 1, 2025 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
Aug 20, 2025

Study contacts

Minglin Lin
Contact
linminglin@sr.gxmu.edu.cn
+86-771-5356529
Ming Qiu
Contact
1347521825@qq.com
+86-771-5356529
Sen Zhang
study director · First Affiliated Hospital of Guangxi Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion